Vaskularni endotelni faktor rasta (VEGF) je signalni protein.[1][2][3] Njega proizvode ćelije koje stimulišu vaskulogenezu i angiogenezu. On je deo sistema koji obnavlja snabdevanje kiseoniom tkiva kad je cirkulacija krvi neadekvatna.
Serumska koncentracija VEGF-a je visoka kod Bronhijalne astme i niska kod dijabetesa. VEGF-ova normalna funkcija je kreiranje novih krvnih sudova tokom embrionskog razvoja, novih krvnih sudova nakon povrede, mišića nakon vežbanja, i novih sudova (kolateralna cirkulacija) za zaobilaženje blokiranih sudova.
Kad je VEGF prekomerno izražen, on može da doprinese bolesti. Čvrsti kanceri ne mogu da rastu izvan ograničene veličine bez adekvatnog pristupa krvi. Kanceri koji izražavaju VEGF imaju sposobnost rasta i metastaze. Prekomerno izražavanje VEGF-a može da uzrokuje vaskularno oboljenje retine oka i drugih delova tela. Lekovi, kao što je bevacizumab, mogu da inhibiraju VEGF i da kontrolišu ili usporavaju razvoj tih bolesti.
Ferrara N, Gerber HP (2002). „The role of vascular endothelial growth factor in angiogenesis”. Acta Haematol. 106 (4): 148—56. PMID11815711. doi:10.1159/000046610.
Orpana A, Salven P (2003). „Angiogenic and lymphangiogenic molecules in hematological malignancies”. Leuk. Lymphoma. 43 (2): 219—24. PMID11999550. doi:10.1080/10428190290005964.
Afuwape AO, Kiriakidis S, Paleolog EM (2003). „The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis”. Histol. Histopathol. 17 (3): 961—72. PMID12168808.
de Bont ES; Neefjes VM; Rosati S; et al. (2003). „New vessel formation and aberrant VEGF/VEGFR signaling in acute leukemia: does it matter?”. Leuk. Lymphoma. 43 (10): 1901—9. PMID12481883. doi:10.1080/1042819021000015844.
Ria R; Roccaro AM; Merchionne F; et al. (2003). „Vascular endothelial growth factor and its receptors in multiple myeloma”. Leukemia. 17 (10): 1961—6. PMID14513045. doi:10.1038/sj.leu.2403076.
Caldwell RB; Bartoli M; Behzadian MA; et al. (2004). „Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives”. Diabetes Metab. Res. Rev. 19 (6): 442—55. PMID14648803. doi:10.1002/dmrr.415.
Eremina V, Quaggin SE (2004). „The role of VEGF-A in glomerular development and function”. Curr. Opin. Nephrol. Hypertens. 13 (1): 9—15. PMID15090854. doi:10.1097/00041552-200401000-00002.
Storkebaum E, Lambrechts D, Carmeliet P (2004). „VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection”. BioEssays. 26 (9): 943—54. PMID15351965. doi:10.1002/bies.20092.
Loureiro RM, D'Amore PA (2005). „Transcriptional regulation of vascular endothelial growth factor in cancer”. Cytokine Growth Factor Rev. 16 (1): 77—89. PMID15733833. doi:10.1016/j.cytogfr.2005.01.005.
Herbst RS, Onn A, Sandler A (2005). „Angiogenesis and lung cancer: prognostic and therapeutic implications”. J. Clin. Oncol. 23 (14): 3243—56. PMID15886312. doi:10.1200/JCO.2005.18.853.
Pufe T; Kurz B; Petersen W; et al. (2006). „The influence of biomechanical parameters on the expression of VEGF and endostatin in the bone and joint system”. Ann. Anat. 187 (5–6): 461—72. PMID16320826. doi:10.1016/j.aanat.2005.06.008.
Tong JP, Yao YF (2006). „Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions”. Clin. Biochem. 39 (3): 267—76. PMID16409998. doi:10.1016/j.clinbiochem.2005.11.013.
Lambrechts D, Carmeliet P (2007). „VEGF at the neurovascular interface: therapeutic implications for motor neuron disease”. Biochim. Biophys. Acta. 1762 (11–12): 1109—21. PMID16784838. doi:10.1016/j.bbadis.2006.04.005.
Matsumoto T, Mugishima H (2006). „Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis”. J. Atheroscler. Thromb. 13 (3): 130—5. PMID16835467. doi:10.5551/jat.13.130.
Mercurio AM, Lipscomb EA, Bachelder RE (2006). „Non-angiogenic functions of VEGF in breast cancer”. Journal of Mammary Gland Biology and Neoplasia. 10 (4): 283—90. PMID16924371. doi:10.1007/s10911-006-9001-9.
Makinde T, Murphy RF, Agrawal DK (2007). „Immunomodulatory role of vascular endothelial growth factor and angiopoietin-1 in airway remodeling”. Curr. Mol. Med. 6 (8): 831—41. PMID17168735. doi:10.2174/156652406779010795.
Rini BI, Rathmell WK (2007). „Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma”. Clin. Cancer Res. 13 (2 Pt 2): 741s—746s. PMID17255303. doi:10.1158/1078-0432.CCR-06-2110.